Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. We are applying our expertise in the development of a portfolio of high-value, differentiated infectious disease therapies, each of which has the potential to significantly improve upon existing standards of care and improve patient outcomes. Our pipeline addresses significant viral and bacterial infections, including herpes zoster (shingles), chronic hepatitis C, and S. aureus infections.

Our strategy is to create value for our shareholders by advancing our development programs through human proof of concept clinical trials and subsequently collaborating with major pharmaceutical companies for late-stage clinical development and subsequent commercialization. We have an existing corporate partnership with Pfizer to develop a staphylococcal vaccine based on our MSCRAMM^® protein platform.